<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367885</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-850/CCT-101</org_study_id>
    <secondary_id>U1111-1166-6015</secondary_id>
    <secondary_id>JapicCTI-152807</secondary_id>
    <nct_id>NCT02367885</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants</brief_title>
  <official_title>An Open-label, Multi-center, Phase 1/2 Study to Evaluate the Safety and Immunogenicity of an Intramuscular Injection of TAK-850 in Healthy Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of an intramuscular
      injection of TAK-850 in healthy pediatric Japanese participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-850, that is under development as a vaccine
      for influenza infection. This study will evaluate the safety and immunogenicity of TAK-850 in
      healthy Japanese children when given as an intramuscular injection.

      The study will enroll approximately 99 participants (33 per treatment group) to receive
      TAK-850 in open label fashion, The participants will be assigned to each treatment group as
      follows:

        -  a single intramuscular injection of TAK-850/0.5 mL in 13 to 19 years old healthy
           Japanese children,

        -  Two injections of TAK-850/0.5 mL in 3 to 12 years old healthy Japanese children,

        -  Two injections of TAK-850/0.25 mL in 6 to 35 months old healthy Japanese children.

      The overall time to participate in this trial is 22 days (13-19 years old) or 43 days (6
      months to 12 years old). Participants will make up to 2 visits (13-19 years old) or 3 visits
      (6 months to 12 years old) to the site.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Solicited Local and Systemic Adverse Events (AEs) for 6-35 Months Old Group</measure>
    <time_frame>Up to 21 days after any vaccination</time_frame>
    <description>Local reactions and systemic events were recorded using a diary. Number of participants with local reactions (Injection site tenderness, Injection site ecchymosis, Irritability postvaccinal) and systemic events (Pyrexia, sweaty, vomiting, crying abnormal, inappetence, somnolence, sleeplessness) were reported. Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Local and Systemic Adverse Events (AEs) for 3-12 Years Old Group and 13-19 Years Old Group</measure>
    <time_frame>Up to 21 days after any vaccination</time_frame>
    <description>Local reactions and systemic events were recorded using a diary. Number of participants with local reactions (Injection site pain, Injection site redness, Injection site swelling, Injection site induration, Injection site tenderness, Injection site ecchymosis) and systemic events (Pyrexia, malaise, chills, fatigue, headache, sweaty, myalgia, nausea, vomiting) were reported. Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 21 days after any vaccination</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event. AEs included both SAE and non-SAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroprotection in Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen) of &gt;=40: 21 Days After the Vaccination for 13-19 Years Old Group</measure>
    <time_frame>Day 22 (21 days after Vaccination)</time_frame>
    <description>Seroprotection rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination for the age group of 13-19 years. Seroprotection rate was defined as the percentage of participants with HI antibody titer of &gt;=40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroprotection in HI Antibody Titer (Egg-Derived Antigen) of &gt;=40: 21 Days After the Second Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</measure>
    <time_frame>Day 43 (21 days after Vaccination 2)</time_frame>
    <description>Seroprotection rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after second vaccination for two age groups: 6-35 months and 3-12 years. Seroprotection rate was defined as the percentage of participants with HI antibody titer of &gt;=40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion in Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen): 21 Days After the Vaccination for 13-19 Years Old Group</measure>
    <time_frame>Day 22 (21 days after Vaccination)</time_frame>
    <description>Seroconversion rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination for the age group of 13-19 years. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from baseline (with a baseline HI antibody titer of &gt;=10), or achieving a HI antibody titer of &gt;=40 (with a baseline HI antibody titer of &lt;10) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion in HI Antibody Titer (Egg-Derived Antigen): 21 Days After the Second Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</measure>
    <time_frame>Day 43 (21 days after Vaccination 2)</time_frame>
    <description>Seroconversion rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after second vaccination for two age groups: 6-35 months and 3-12 years. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from baseline (with a baseline HI antibody titer of &gt;=10), or achieving a HI antibody titer of &gt;=40 (with a baseline HI antibody titer of &lt;10) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Increase (GMFI) in HI Antibody Titer (Egg-Derived Antigen) From Baseline to 21 Days After the Vaccination for 13-19 Years Old Group</measure>
    <time_frame>Day 22 (21 days after Vaccination)</time_frame>
    <description>GMFI from baseline in HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination for the age group of 13-19 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMFI in HI Antibody Titer (Egg-Derived Antigen) From Baseline to 21 Days After the Second Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</measure>
    <time_frame>Day 43 (21 days after Vaccination 2)</time_frame>
    <description>GMFI from baseline in HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after second vaccination for two age groups: 6-35 months and 3-12 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection in HI Antibody Titer (Egg-Derived Antigen) of &gt;= 40: 21 Days After the First Vaccination for 6-35 Months Old Group and 3-12- Years Old Group</measure>
    <time_frame>Day 22 (21 days after Vaccination 1)</time_frame>
    <description>Seroprotection rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after first vaccination for two age groups: 6-35 months and 3-12 years. Seroprotection rate was defined as the percentage of participants with HI antibody titer of &gt;=40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion in HI Antibody Titer (Egg-Derived Antigen): 21 Days After the First Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</measure>
    <time_frame>Day 22 (21 days after Vaccination 1)</time_frame>
    <description>Seroconversion rate was measured by HI antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after the first vaccination for two age groups: 6-35 months and 3-12 years. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from baseline (with a baseline HI antibody titer of &gt;=10), or achieving a HI antibody titer of &gt;=40 (with baseline HI antibody titer of &lt;10) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFI in HI Antibody Titer (Egg-Derived Antigen) From Baseline to 21 Days After the First Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</measure>
    <time_frame>Day 22 (21 days after Vaccination 1)</time_frame>
    <description>GMFI from baseline in HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after first vaccination for two age groups: 6-35 months and 3-12 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of HI Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
    <description>GMT of HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination. Analysis after Vaccination 2 is only applicable for 6-35 Months old group and 3-12 Years old group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection in Single Radial Hemolysis (SRH) Antibody Titer (Egg- Derived Antigen) of &gt;=25 Square Millimeter (mm^2)</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
    <description>Seroprotection rate was measured by SRH antibody titer (egg- derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroprotection rate was defined as the percentage of participants with SRH antibody titer of &gt;=25 mm^2. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion in SRH Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
    <description>Seroconversion rate was measured by SRH antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroconversion rate was defined as the percentage of participants achieving a minimal 50% increase from baseline (with a baseline SRH antibody titer of &gt;4 mm^2) or achieving a SRH antibody titer of &gt;=25 mm^2 (with baseline SRH antibody titer of &lt;=4 mm^2) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain). Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFI in SRH Antibody Titer (Egg-Derived Antigen) From Baseline to 21 Days After Each Vaccination</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6 -35 months old group and 3-12 years old group)</time_frame>
    <description>GMFI from baseline in SRH antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of SRH Antibody Titer (Egg-Derived Antigen)</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
    <description>GMT of SRH antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection in HI Antibody Titer (Vero Antigen) of &gt;=40</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
    <description>Seroprotection rate was measured by HI antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroprotection rate was defined as the percentage of participants with HI antibody titer of &gt;=40. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion in HI Antibody Titer (Vero Antigen)</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
    <description>Seroconversion rate was measured by HI antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from baseline (with a baseline HI antibody titer of &gt;=10), or achieving a HI antibody titer of &gt;=40 (with baseline HI antibody titer of &lt;10) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain). Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFI in HI Antibody Titer (Vero Antigen) From Baseline to 21 Days After Each Vaccination</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
    <description>GMFI from baseline in HI antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of HI Antibody Titer (Vero Antigen)</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
    <description>GMT of HI antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection in SRH Antibody Titer (Vero Antigen) of &gt;= 25 mm^2</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
    <description>Seroprotection rate was measured by SRH antibody titer (Vero Antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroprotection rate was defined as the percentage of participants with SRH antibody titer of &gt;=25 mm^2. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion in SRH Antibody Titer (Vero Antigen)</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
    <description>Seroconversion rate was measured by SRH antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroconversion rate was defined as the percentage of participants achieving a minimal 50% increase from baseline (with a baseline SRH antibody titer of &gt;4 mm^2), or achieving a SRH antibody titer of &gt;=25 mm^2 (with baseline SRH antibody titer of &lt;=4 mm^2) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain). Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFI in SRH Antibody Titer (Vero Antigen) From Baseline to 21 Days After Each Vaccination</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
    <description>GMFI from baseline in SRH antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of SRH Antibody Titer (Vero Antigen)</measure>
    <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
    <description>GMT of SRH antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Influenza Infection</condition>
  <arm_group>
    <arm_group_label>TAK-850 0.5 mL injection (13-19 years of age)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intramuscular injection of TAK-850 0.5 mL in participants aged 13-19 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-850 0.5 mL injection (3-12 years of age)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two intramuscular injections of TAK-850 0.5 mL in participants aged 3-12 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-850 0.25 mL injection (6-35 months of age)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two intramuscular injections of TAK-850 0.25 mL in participants aged 6-35 months old.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-850 0.5 mL injection</intervention_name>
    <description>TAK-850 injection</description>
    <arm_group_label>TAK-850 0.5 mL injection (13-19 years of age)</arm_group_label>
    <arm_group_label>TAK-850 0.5 mL injection (3-12 years of age)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-850 0.25 mL injection</intervention_name>
    <description>TAK-850 intramuscular injection</description>
    <arm_group_label>TAK-850 0.25 mL injection (6-35 months of age)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the investigator or the subinvestigator, the participant and/or
             his/her representative and his/her guardian is capable of understanding and complying
             with protocol requirements.

          2. The participant's representative can sign and date a written, informed consent form
             prior to the initiation of any study procedures.

          3. The participant is a healthy Japanese child.

          4. The participant is aged 6 months to 19 years, inclusive, at the time of starting to
             receive the study vaccine.

          5. A female participant of childbearing potential who is sexually active with a
             nonsterilized male partner agrees to routinely use adequate contraception from signing
             of informed consent until 12 weeks after the administration.

        Exclusion Criteria:

        [Only for participants at the age of 6-35 months old]

          1. The participant is a preterm newborn (gestational age was less than 37 weeks) or a
             low-birth-weight newborn (birth weight was less than 2500 g).

          2. The participant has received any investigational compound within 4 months prior to the
             initial injection of study vaccine.

          3. The participant has been vaccinated with seasonal influenza vaccine within 6 months
             prior to the initial injection of study vaccine.

          4. The participant has a history of influenza infection within 6 months prior to the
             initial injection of study vaccine.

          5. The participant is a study site employee, an immediate family member of such an
             employee, or in a dependent relationship with a study site employee who is involved in
             the conduct of this study (e.g., spouse, parent, child, sibling), or may consent under
             duress.

          6. The participant has uncontrolled, clinically significant manifestations of
             neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal,
             endocrine or other disorders, which may impact the ability of the participant to
             participate or potentially confound the study results.

          7. The participant has an armpit temperature ≥ 37.5°C prior to the initial injection of
             study vaccine on Day 1.

          8. The participant has any medically diagnosed or suspected immune deficient condition.

          9. The participant has an immune compromising condition or disease, or is currently
             undergoing a form of treatment or was undergoing a form of treatment that can be
             expected to influence immune response within 30 days prior to the initial injection of
             study vaccine. Such treatments include, but are not limited to, systemic or high dose
             inhaled corticosteroids (&gt; 800 μg/day of beclomethasone dipropionate or equivalent;
             the use of inhaled and nasal steroids that do not exceed this level will be
             permitted), radiation treatment or other immunosuppressive or cytotoxic drugs.

         10. The participant has received antipyretics within 4 hours prior to the initial
             injection of study vaccine.

         11. The participant has a history of Guillain-Barré Syndrome, demyelinating disorders
             (including acute disseminated encephalomyelitis [ADEM] and multiple sclerosis) or
             convulsions.

         12. The participant has a functional or surgical asplenia.

         13. The participant has a rash, other dermatologic conditions or tattoos which may
             interfere with the evaluation of injection site reaction as determined by the
             Investigator.

         14. The participant has a history of, or is infected with the Hepatitis B Virus (HBsAgs),
             Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV).

         15. The participant has a known hypersensitivity to any component of TAK-850.

         16. The participant has a history of severe allergic reactions or anaphylaxis.

         17. The participant has a history of drug abuse (defined as any illicit drug use) or a
             history of alcohol abuse within 1 year prior to the initial injection of study vaccine
             or is unwilling to agree to abstain from alcohol and drugs throughout the study.

         18. The participant has received any blood products (e.g. blood transfusion or
             immunoglobulin) within 90 days prior to the initial injection of study vaccine.

         19. The participant has received a live vaccine within 4 weeks (28 days) or an inactivated
             vaccine within 2 weeks (14 days) prior to the initial injection of study vaccine.

         20. If female, the participant is pregnant or lactating or intending to become pregnant
             before signing informed consent, during, or within 1 month after participating in this
             study; or intending to donate ova during such time period.

         21. The participant has donated whole blood ≥ 200 mL within 4 weeks (28 days), ≥ 400 mL
             within 12 weeks (84 days), ≥ 800 mL within 52 weeks (364 days), or blood components
             within 2 weeks (14 days) prior to the initial injection of study vaccine.

         22. In the opinion of the investigator or subinvestigator, the participant is unlikely to
             comply with protocol requirements or is considered ineligible for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chuou-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <results_first_submitted>March 8, 2016</results_first_submitted>
  <results_first_submitted_qc>March 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 7, 2016</results_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 2 investigative sites in Japan from 14 February 2015 to 2 May 2015.</recruitment_details>
      <pre_assignment_details>Healthy pediatric participants of age group 6 months-19 years were enrolled in 1 of the 3 treatment groups: TAK-850 0.25 milliliter (mL): 6 - 35 months; TAK-850 0.5 mL: 3-12 Years and TAK-850 0.5 mL: 13-19 Years.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAK-850 0.25 mL: 6-35 Months</title>
          <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
        </group>
        <group group_id="P2">
          <title>TAK-850 0.5 mL: 3-12 Years</title>
          <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
        </group>
        <group group_id="P3">
          <title>TAK-850 0.5 mL: 13-19 Years</title>
          <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all participants who received at least 1 dose of study vaccination.</population>
      <group_list>
        <group group_id="B1">
          <title>TAK-850 0.25 mL: 6-35 Months</title>
          <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
        </group>
        <group group_id="B2">
          <title>TAK-850 0.5 mL: 3-12 Years</title>
          <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
        </group>
        <group group_id="B3">
          <title>TAK-850 0.5 mL: 13-19 Years</title>
          <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6-35 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-12 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13-19 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemagglutination Inhibition (HI) (Egg-derived) - A/H1N1 Titer at Day 1(Pre-vaccination)</title>
          <description>Number of participants with values of HI antibody titer for A/H1N1 strain pre-vaccination at Day 1 were reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less Than (&lt;) 40 Titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater Than or Equal to (&gt;=) 40 Titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemagglutination Inhibition (HI) (Egg-derived) - A/H3N2 Titer at Day 1 (Pre-vaccination)</title>
          <description>Number of participants with values of HI antibody titer for A/H3N2 strain pre-vaccination at Day 1 were reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;40 Titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 Titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemagglutination Inhibition (HI) (Egg-derived) - B Titer at Day 1 (Pre-vaccination)</title>
          <description>Number of participants with values of HI antibody titer for B strain pre-vaccination at Day 1 were reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;40 Titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 Titer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Influenza Infection within 5 years</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Infection occurred</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection did not occur</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Administration of Antipyretics</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Antipyretics administered</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretics not administered</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Local and Systemic Adverse Events (AEs) for 6-35 Months Old Group</title>
        <description>Local reactions and systemic events were recorded using a diary. Number of participants with local reactions (Injection site tenderness, Injection site ecchymosis, Irritability postvaccinal) and systemic events (Pyrexia, sweaty, vomiting, crying abnormal, inappetence, somnolence, sleeplessness) were reported. Participants may be represented in more than 1 category.</description>
        <time_frame>Up to 21 days after any vaccination</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local and Systemic Adverse Events (AEs) for 6-35 Months Old Group</title>
          <description>Local reactions and systemic events were recorded using a diary. Number of participants with local reactions (Injection site tenderness, Injection site ecchymosis, Irritability postvaccinal) and systemic events (Pyrexia, sweaty, vomiting, crying abnormal, inappetence, somnolence, sleeplessness) were reported. Participants may be represented in more than 1 category.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study vaccination.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweaty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability postvaccinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inappetence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleeplessness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Local and Systemic Adverse Events (AEs) for 3-12 Years Old Group and 13-19 Years Old Group</title>
        <description>Local reactions and systemic events were recorded using a diary. Number of participants with local reactions (Injection site pain, Injection site redness, Injection site swelling, Injection site induration, Injection site tenderness, Injection site ecchymosis) and systemic events (Pyrexia, malaise, chills, fatigue, headache, sweaty, myalgia, nausea, vomiting) were reported. Participants may be represented in more than 1 category.</description>
        <time_frame>Up to 21 days after any vaccination</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local and Systemic Adverse Events (AEs) for 3-12 Years Old Group and 13-19 Years Old Group</title>
          <description>Local reactions and systemic events were recorded using a diary. Number of participants with local reactions (Injection site pain, Injection site redness, Injection site swelling, Injection site induration, Injection site tenderness, Injection site ecchymosis) and systemic events (Pyrexia, malaise, chills, fatigue, headache, sweaty, myalgia, nausea, vomiting) were reported. Participants may be represented in more than 1 category.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study vaccination.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweaty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event. AEs included both SAE and non-SAE.</description>
        <time_frame>Up to 21 days after any vaccination</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event. AEs included both SAE and non-SAE.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study vaccination.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroprotection in Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen) of &gt;=40: 21 Days After the Vaccination for 13-19 Years Old Group</title>
        <description>Seroprotection rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination for the age group of 13-19 years. Seroprotection rate was defined as the percentage of participants with HI antibody titer of &gt;=40.</description>
        <time_frame>Day 22 (21 days after Vaccination)</time_frame>
        <population>All participants included in the full analysis set (FAS) (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection in Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen) of &gt;=40: 21 Days After the Vaccination for 13-19 Years Old Group</title>
          <description>Seroprotection rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination for the age group of 13-19 years. Seroprotection rate was defined as the percentage of participants with HI antibody titer of &gt;=40.</description>
          <population>All participants included in the full analysis set (FAS) (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" lower_limit="84.241" upper_limit="99.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9" lower_limit="79.774" upper_limit="99.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="48.173" upper_limit="82.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroprotection in HI Antibody Titer (Egg-Derived Antigen) of &gt;=40: 21 Days After the Second Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</title>
        <description>Seroprotection rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after second vaccination for two age groups: 6-35 months and 3-12 years. Seroprotection rate was defined as the percentage of participants with HI antibody titer of &gt;=40.</description>
        <time_frame>Day 43 (21 days after Vaccination 2)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection in HI Antibody Titer (Egg-Derived Antigen) of &gt;=40: 21 Days After the Second Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</title>
          <description>Seroprotection rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after second vaccination for two age groups: 6-35 months and 3-12 years. Seroprotection rate was defined as the percentage of participants with HI antibody titer of &gt;=40.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain (n=31, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1" lower_limit="70.166" upper_limit="96.370"/>
                    <measurement group_id="O2" value="100" lower_limit="88.781" upper_limit="100.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain (n=31, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="51.964" upper_limit="85.777"/>
                    <measurement group_id="O2" value="90.3" lower_limit="74.246" upper_limit="97.958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain (n=31, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="2.042" upper_limit="25.754"/>
                    <measurement group_id="O2" value="45.2" lower_limit="27.316" upper_limit="63.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion in Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen): 21 Days After the Vaccination for 13-19 Years Old Group</title>
        <description>Seroconversion rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination for the age group of 13-19 years. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from baseline (with a baseline HI antibody titer of &gt;=10), or achieving a HI antibody titer of &gt;=40 (with a baseline HI antibody titer of &lt;10) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain).</description>
        <time_frame>Day 22 (21 days after Vaccination)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion in Hemagglutination Inhibition (HI) Antibody Titer (Egg-Derived Antigen): 21 Days After the Vaccination for 13-19 Years Old Group</title>
          <description>Seroconversion rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination for the age group of 13-19 years. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from baseline (with a baseline HI antibody titer of &gt;=10), or achieving a HI antibody titer of &gt;=40 (with a baseline HI antibody titer of &lt;10) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain).</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="48.173" upper_limit="82.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="28.107" upper_limit="63.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="28.107" upper_limit="63.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion in HI Antibody Titer (Egg-Derived Antigen): 21 Days After the Second Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</title>
        <description>Seroconversion rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after second vaccination for two age groups: 6-35 months and 3-12 years. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from baseline (with a baseline HI antibody titer of &gt;=10), or achieving a HI antibody titer of &gt;=40 (with a baseline HI antibody titer of &lt;10) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain).</description>
        <time_frame>Day 43 (21 days after Vaccination 2)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion in HI Antibody Titer (Egg-Derived Antigen): 21 Days After the Second Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</title>
          <description>Seroconversion rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after second vaccination for two age groups: 6-35 months and 3-12 years. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from baseline (with a baseline HI antibody titer of &gt;=10), or achieving a HI antibody titer of &gt;=40 (with a baseline HI antibody titer of &lt;10) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain).</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain (n=31, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6" lower_limit="62.527" upper_limit="92.548"/>
                    <measurement group_id="O2" value="71.0" lower_limit="51.964" upper_limit="85.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain (n=31, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1" lower_limit="39.076" upper_limit="75.452"/>
                    <measurement group_id="O2" value="54.8" lower_limit="36.034" upper_limit="72.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain (n=31, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="2.042" upper_limit="25.754"/>
                    <measurement group_id="O2" value="45.2" lower_limit="27.316" upper_limit="63.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Increase (GMFI) in HI Antibody Titer (Egg-Derived Antigen) From Baseline to 21 Days After the Vaccination for 13-19 Years Old Group</title>
        <description>GMFI from baseline in HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination for the age group of 13-19 years.</description>
        <time_frame>Day 22 (21 days after Vaccination)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Increase (GMFI) in HI Antibody Titer (Egg-Derived Antigen) From Baseline to 21 Days After the Vaccination for 13-19 Years Old Group</title>
          <description>GMFI from baseline in HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after vaccination for the age group of 13-19 years.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.53" lower_limit="6.340" upper_limit="28.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" lower_limit="2.212" upper_limit="6.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" lower_limit="2.374" upper_limit="5.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GMFI in HI Antibody Titer (Egg-Derived Antigen) From Baseline to 21 Days After the Second Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</title>
        <description>GMFI from baseline in HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after second vaccination for two age groups: 6-35 months and 3-12 years.</description>
        <time_frame>Day 43 (21 days after Vaccination 2)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in HI Antibody Titer (Egg-Derived Antigen) From Baseline to 21 Days After the Second Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</title>
          <description>GMFI from baseline in HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after second vaccination for two age groups: 6-35 months and 3-12 years.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain (n=31, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.23" lower_limit="8.856" upper_limit="22.857"/>
                    <measurement group_id="O2" value="6.15" lower_limit="4.076" upper_limit="9.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain (n=31, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.85" lower_limit="3.728" upper_limit="9.183"/>
                    <measurement group_id="O2" value="4.73" lower_limit="2.882" upper_limit="7.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain (n=31, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="0.958" upper_limit="1.825"/>
                    <measurement group_id="O2" value="2.86" lower_limit="1.823" upper_limit="4.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection in HI Antibody Titer (Egg-Derived Antigen) of &gt;= 40: 21 Days After the First Vaccination for 6-35 Months Old Group and 3-12- Years Old Group</title>
        <description>Seroprotection rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after first vaccination for two age groups: 6-35 months and 3-12 years. Seroprotection rate was defined as the percentage of participants with HI antibody titer of &gt;=40.</description>
        <time_frame>Day 22 (21 days after Vaccination 1)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection in HI Antibody Titer (Egg-Derived Antigen) of &gt;= 40: 21 Days After the First Vaccination for 6-35 Months Old Group and 3-12- Years Old Group</title>
          <description>Seroprotection rate was measured by HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after first vaccination for two age groups: 6-35 months and 3-12 years. Seroprotection rate was defined as the percentage of participants with HI antibody titer of &gt;=40.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain (n=32, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="5.275" upper_limit="32.788"/>
                    <measurement group_id="O2" value="93.8" lower_limit="79.193" upper_limit="99.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain (n=32, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="13.746" upper_limit="46.747"/>
                    <measurement group_id="O2" value="75.0" lower_limit="56.595" upper_limit="88.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain (n=32, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="0.766" upper_limit="20.807"/>
                    <measurement group_id="O2" value="46.9" lower_limit="29.094" upper_limit="65.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion in HI Antibody Titer (Egg-Derived Antigen): 21 Days After the First Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</title>
        <description>Seroconversion rate was measured by HI antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after the first vaccination for two age groups: 6-35 months and 3-12 years. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from baseline (with a baseline HI antibody titer of &gt;=10), or achieving a HI antibody titer of &gt;=40 (with baseline HI antibody titer of &lt;10) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain).</description>
        <time_frame>Day 22 (21 days after Vaccination 1)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion in HI Antibody Titer (Egg-Derived Antigen): 21 Days After the First Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</title>
          <description>Seroconversion rate was measured by HI antibody titer for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after the first vaccination for two age groups: 6-35 months and 3-12 years. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from baseline (with a baseline HI antibody titer of &gt;=10), or achieving a HI antibody titer of &gt;=40 (with baseline HI antibody titer of &lt;10) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain).</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain (n=32, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="1.977" upper_limit="25.023"/>
                    <measurement group_id="O2" value="53.1" lower_limit="34.744" upper_limit="70.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain (n=32, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="5.275" upper_limit="32.788"/>
                    <measurement group_id="O2" value="37.5" lower_limit="21.100" upper_limit="56.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain (n=32, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="0.766" upper_limit="20.807"/>
                    <measurement group_id="O2" value="46.9" lower_limit="29.094" upper_limit="65.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFI in HI Antibody Titer (Egg-Derived Antigen) From Baseline to 21 Days After the First Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</title>
        <description>GMFI from baseline in HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after first vaccination for two age groups: 6-35 months and 3-12 years.</description>
        <time_frame>Day 22 (21 days after Vaccination 1)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in HI Antibody Titer (Egg-Derived Antigen) From Baseline to 21 Days After the First Vaccination for 6-35 Months Old Group and 3-12 Years Old Group</title>
          <description>GMFI from baseline in HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after first vaccination for two age groups: 6-35 months and 3-12 years.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time point.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Strain (n=32, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" lower_limit="1.059" upper_limit="1.888"/>
                    <measurement group_id="O2" value="5.36" lower_limit="3.221" upper_limit="8.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Strain (n=32, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit="1.158" upper_limit="2.145"/>
                    <measurement group_id="O2" value="3.15" lower_limit="2.020" upper_limit="4.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Strain (n=32, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" lower_limit="0.907" upper_limit="1.628"/>
                    <measurement group_id="O2" value="3.22" lower_limit="1.972" upper_limit="5.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of HI Antibody Titer (Egg-Derived Antigen)</title>
        <description>GMT of HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination. Analysis after Vaccination 2 is only applicable for 6-35 Months old group and 3-12 Years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in FAS (all participants who received at least 1 dose of study vaccination) who had available data for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of HI Antibody Titer (Egg-Derived Antigen)</title>
          <description>GMT of HI antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination. Analysis after Vaccination 2 is only applicable for 6-35 Months old group and 3-12 Years old group.</description>
          <population>All participants included in FAS (all participants who received at least 1 dose of study vaccination) who had available data for specified strain at specified post-baseline time points.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32,32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.78" lower_limit="5.872" upper_limit="13.132"/>
                    <measurement group_id="O2" value="583.71" lower_limit="351.985" upper_limit="967.995"/>
                    <measurement group_id="O3" value="558.32" lower_limit="391.258" upper_limit="796.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=31,31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.96" lower_limit="57.072" upper_limit="138.677"/>
                    <measurement group_id="O2" value="773.95" lower_limit="576.157" upper_limit="1039.645"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32,32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.56" lower_limit="9.046" upper_limit="34.086"/>
                    <measurement group_id="O2" value="87.24" lower_limit="47.894" upper_limit="158.908"/>
                    <measurement group_id="O3" value="133.14" lower_limit="86.409" upper_limit="205.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=31,31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.90" lower_limit="38.136" upper_limit="117.347"/>
                    <measurement group_id="O2" value="127.94" lower_limit="76.820" upper_limit="213.092"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n=32,32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.08" lower_limit="4.535" upper_limit="8.141"/>
                    <measurement group_id="O2" value="16.82" lower_limit="10.192" upper_limit="27.751"/>
                    <measurement group_id="O3" value="28.58" lower_limit="18.421" upper_limit="44.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 2 (n=31,31,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.61" lower_limit="4.790" upper_limit="9.127"/>
                    <measurement group_id="O2" value="14.96" lower_limit="9.400" upper_limit="23.792"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection in Single Radial Hemolysis (SRH) Antibody Titer (Egg- Derived Antigen) of &gt;=25 Square Millimeter (mm^2)</title>
        <description>Seroprotection rate was measured by SRH antibody titer (egg- derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroprotection rate was defined as the percentage of participants with SRH antibody titer of &gt;=25 mm^2. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection in Single Radial Hemolysis (SRH) Antibody Titer (Egg- Derived Antigen) of &gt;=25 Square Millimeter (mm^2)</title>
          <description>Seroprotection rate was measured by SRH antibody titer (egg- derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroprotection rate was defined as the percentage of participants with SRH antibody titer of &gt;=25 mm^2. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="1.977" upper_limit="25.023"/>
                    <measurement group_id="O2" value="90.6" lower_limit="74.977" upper_limit="98.023"/>
                    <measurement group_id="O3" value="100" lower_limit="89.424" upper_limit="100.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" lower_limit="60.275" upper_limit="92.006"/>
                    <measurement group_id="O2" value="100" lower_limit="88.781" upper_limit="100.000"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="13.746" upper_limit="46.747"/>
                    <measurement group_id="O2" value="78.1" lower_limit="60.027" upper_limit="90.723"/>
                    <measurement group_id="O3" value="97.0" lower_limit="84.241" upper_limit="99.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" lower_limit="60.275" upper_limit="92.006"/>
                    <measurement group_id="O2" value="93.5" lower_limit="78.578" upper_limit="99.209"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="5.275" upper_limit="32.788"/>
                    <measurement group_id="O2" value="78.1" lower_limit="60.027" upper_limit="90.723"/>
                    <measurement group_id="O3" value="97.0" lower_limit="84.241" upper_limit="99.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" lower_limit="29.449" upper_limit="67.469"/>
                    <measurement group_id="O2" value="87.1" lower_limit="70.166" upper_limit="96.370"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion in SRH Antibody Titer (Egg-Derived Antigen)</title>
        <description>Seroconversion rate was measured by SRH antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroconversion rate was defined as the percentage of participants achieving a minimal 50% increase from baseline (with a baseline SRH antibody titer of &gt;4 mm^2) or achieving a SRH antibody titer of &gt;=25 mm^2 (with baseline SRH antibody titer of &lt;=4 mm^2) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain). Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion in SRH Antibody Titer (Egg-Derived Antigen)</title>
          <description>Seroconversion rate was measured by SRH antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroconversion rate was defined as the percentage of participants achieving a minimal 50% increase from baseline (with a baseline SRH antibody titer of &gt;4 mm^2) or achieving a SRH antibody titer of &gt;=25 mm^2 (with baseline SRH antibody titer of &lt;=4 mm^2) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain). Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32,32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="0.766" upper_limit="20.807"/>
                    <measurement group_id="O2" value="81.3" lower_limit="63.561" upper_limit="92.792"/>
                    <measurement group_id="O3" value="72.7" lower_limit="54.476" upper_limit="86.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=29,31,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" lower_limit="60.275" upper_limit="92.006"/>
                    <measurement group_id="O2" value="90.3" lower_limit="74.246" upper_limit="97.958"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32,32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="7.208" upper_limit="36.439"/>
                    <measurement group_id="O2" value="46.9" lower_limit="29.094" upper_limit="65.256"/>
                    <measurement group_id="O3" value="42.4" lower_limit="25.476" upper_limit="60.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=29,31,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="49.168" upper_limit="84.715"/>
                    <measurement group_id="O2" value="67.7" lower_limit="48.627" upper_limit="83.318"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n=32,32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="5.275" upper_limit="32.788"/>
                    <measurement group_id="O2" value="62.5" lower_limit="43.692" upper_limit="78.900"/>
                    <measurement group_id="O3" value="42.4" lower_limit="25.476" upper_limit="60.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 2 (n=29,31,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" lower_limit="29.449" upper_limit="67.469"/>
                    <measurement group_id="O2" value="74.2" lower_limit="55.387" upper_limit="88.144"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFI in SRH Antibody Titer (Egg-Derived Antigen) From Baseline to 21 Days After Each Vaccination</title>
        <description>GMFI from baseline in SRH antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6 -35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in SRH Antibody Titer (Egg-Derived Antigen) From Baseline to 21 Days After Each Vaccination</title>
          <description>GMFI from baseline in SRH antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2020" lower_limit="0.98289" upper_limit="1.46989"/>
                    <measurement group_id="O2" value="2.4707" lower_limit="1.89898" upper_limit="3.21447"/>
                    <measurement group_id="O3" value="2.7540" lower_limit="1.97811" upper_limit="3.83430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0652" lower_limit="4.91411" upper_limit="10.15793"/>
                    <measurement group_id="O2" value="2.9292" lower_limit="2.23349" upper_limit="3.84174"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5038" lower_limit="1.18040" upper_limit="1.91588"/>
                    <measurement group_id="O2" value="1.9682" lower_limit="1.57520" upper_limit="2.45935"/>
                    <measurement group_id="O3" value="2.0612" lower_limit="1.51354" upper_limit="2.80709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1163" lower_limit="3.65073" upper_limit="7.17028"/>
                    <measurement group_id="O2" value="2.3363" lower_limit="1.77098" upper_limit="3.08201"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3443" lower_limit="1.03252" upper_limit="1.75027"/>
                    <measurement group_id="O2" value="2.8400" lower_limit="1.98458" upper_limit="4.06424"/>
                    <measurement group_id="O3" value="1.8889" lower_limit="1.42420" upper_limit="2.50523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B:21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7658" lower_limit="2.66600" upper_limit="5.31917"/>
                    <measurement group_id="O2" value="3.8880" lower_limit="2.72038" upper_limit="5.55686"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT of SRH Antibody Titer (Egg-Derived Antigen)</title>
        <description>GMT of SRH antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT of SRH Antibody Titer (Egg-Derived Antigen)</title>
          <description>GMT of SRH antibody titer (egg-derived antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1604" lower_limit="4.01580" upper_limit="6.63117"/>
                    <measurement group_id="O2" value="64.4700" lower_limit="45.99985" upper_limit="90.35654"/>
                    <measurement group_id="O3" value="89.8328" lower_limit="82.79308" upper_limit="97.47116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5555" lower_limit="21.50430" upper_limit="43.41647"/>
                    <measurement group_id="O2" value="83.8136" lower_limit="74.30566" upper_limit="94.53822"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8918" lower_limit="6.28974" upper_limit="15.55675"/>
                    <measurement group_id="O2" value="36.4508" lower_limit="26.86516" upper_limit="49.45654"/>
                    <measurement group_id="O3" value="52.9301" lower_limit="46.41297" upper_limit="60.36242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0272" lower_limit="24.40664" upper_limit="44.69260"/>
                    <measurement group_id="O2" value="46.7134" lower_limit="37.50756" upper_limit="58.17885"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3066" lower_limit="4.34309" upper_limit="9.15778"/>
                    <measurement group_id="O2" value="41.4710" lower_limit="29.47979" upper_limit="58.33961"/>
                    <measurement group_id="O3" value="70.2017" lower_limit="58.66371" upper_limit="84.00902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9727" lower_limit="11.66290" upper_limit="24.69991"/>
                    <measurement group_id="O2" value="52.8247" lower_limit="44.14357" upper_limit="63.21315"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection in HI Antibody Titer (Vero Antigen) of &gt;=40</title>
        <description>Seroprotection rate was measured by HI antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroprotection rate was defined as the percentage of participants with HI antibody titer of &gt;=40. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection in HI Antibody Titer (Vero Antigen) of &gt;=40</title>
          <description>Seroprotection rate was measured by HI antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroprotection rate was defined as the percentage of participants with HI antibody titer of &gt;=40. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="0.079" upper_limit="16.217"/>
                    <measurement group_id="O2" value="90.6" lower_limit="74.977" upper_limit="98.023"/>
                    <measurement group_id="O3" value="90.9" lower_limit="75.668" upper_limit="98.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=31, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="16.682" upper_limit="51.373"/>
                    <measurement group_id="O2" value="93.5" lower_limit="78.578" upper_limit="99.209"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="13.746" upper_limit="46.747"/>
                    <measurement group_id="O2" value="81.3" lower_limit="63.561" upper_limit="92.792"/>
                    <measurement group_id="O3" value="97.0" lower_limit="84.241" upper_limit="99.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=31,31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" lower_limit="55.387" upper_limit="88.144"/>
                    <measurement group_id="O2" value="87.1" lower_limit="70.166" upper_limit="96.370"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="1.977" upper_limit="25.023"/>
                    <measurement group_id="O2" value="34.4" lower_limit="18.572" upper_limit="53.193"/>
                    <measurement group_id="O3" value="48.5" lower_limit="30.796" upper_limit="66.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 2 (n=31, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="2.042" upper_limit="25.754"/>
                    <measurement group_id="O2" value="51.6" lower_limit="33.061" upper_limit="69.845"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion in HI Antibody Titer (Vero Antigen)</title>
        <description>Seroconversion rate was measured by HI antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from baseline (with a baseline HI antibody titer of &gt;=10), or achieving a HI antibody titer of &gt;=40 (with baseline HI antibody titer of &lt;10) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain). Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion in HI Antibody Titer (Vero Antigen)</title>
          <description>Seroconversion rate was measured by HI antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroconversion rate was defined as the percentage of participants achieving a minimal 4-fold increase from baseline (with a baseline HI antibody titer of &gt;=10), or achieving a HI antibody titer of &gt;=40 (with baseline HI antibody titer of &lt;10) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain). Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.000" upper_limit="10.888"/>
                    <measurement group_id="O2" value="78.1" lower_limit="60.027" upper_limit="90.723"/>
                    <measurement group_id="O3" value="69.7" lower_limit="51.289" upper_limit="84.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=31, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="16.682" upper_limit="51.373"/>
                    <measurement group_id="O2" value="87.1" lower_limit="70.166" upper_limit="96.370"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" lower_limit="9.277" upper_limit="39.973"/>
                    <measurement group_id="O2" value="43.8" lower_limit="26.364" upper_limit="62.337"/>
                    <measurement group_id="O3" value="42.4" lower_limit="25.476" upper_limit="60.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=31,31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7" lower_limit="48.627" upper_limit="83.318"/>
                    <measurement group_id="O2" value="54.8" lower_limit="36.034" upper_limit="72.684"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="1.977" upper_limit="25.023"/>
                    <measurement group_id="O2" value="28.1" lower_limit="13.746" upper_limit="46.747"/>
                    <measurement group_id="O3" value="42.4" lower_limit="25.476" upper_limit="60.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 2 (n=31, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="2.042" upper_limit="25.754"/>
                    <measurement group_id="O2" value="48.4" lower_limit="30.155" upper_limit="66.939"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFI in HI Antibody Titer (Vero Antigen) From Baseline to 21 Days After Each Vaccination</title>
        <description>GMFI from baseline in HI antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in HI Antibody Titer (Vero Antigen) From Baseline to 21 Days After Each Vaccination</title>
          <description>GMFI from baseline in HI antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.978" upper_limit="1.068"/>
                    <measurement group_id="O2" value="16.17" lower_limit="9.606" upper_limit="27.233"/>
                    <measurement group_id="O3" value="7.51" lower_limit="4.800" upper_limit="11.754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=31, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" lower_limit="1.472" upper_limit="3.592"/>
                    <measurement group_id="O2" value="17.30" lower_limit="10.589" upper_limit="28.268"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="1.264" upper_limit="2.338"/>
                    <measurement group_id="O2" value="3.67" lower_limit="2.250" upper_limit="5.979"/>
                    <measurement group_id="O3" value="3.90" lower_limit="2.387" upper_limit="6.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=31, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.40" lower_limit="4.110" upper_limit="9.954"/>
                    <measurement group_id="O2" value="4.78" lower_limit="2.937" upper_limit="7.791"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" lower_limit="0.965" upper_limit="1.669"/>
                    <measurement group_id="O2" value="2.62" lower_limit="1.695" upper_limit="4.055"/>
                    <measurement group_id="O3" value="3.21" lower_limit="2.130" upper_limit="4.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 2 (n=31, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" lower_limit="0.964" upper_limit="1.697"/>
                    <measurement group_id="O2" value="2.99" lower_limit="1.918" upper_limit="4.663"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT of HI Antibody Titer (Vero Antigen)</title>
        <description>GMT of HI antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT of HI Antibody Titer (Vero Antigen)</title>
          <description>GMT of HI antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.34" lower_limit="4.673" upper_limit="6.092"/>
                    <measurement group_id="O2" value="156.57" lower_limit="99.959" upper_limit="245.257"/>
                    <measurement group_id="O3" value="69.79" lower_limit="49.992" upper_limit="97.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=31, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.03" lower_limit="7.571" upper_limit="19.101"/>
                    <measurement group_id="O2" value="187.11" lower_limit="123.079" upper_limit="284.443"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.46" lower_limit="8.314" upper_limit="32.578"/>
                    <measurement group_id="O2" value="94.11" lower_limit="50.943" upper_limit="173.861"/>
                    <measurement group_id="O3" value="141.80" lower_limit="102.494" upper_limit="196.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=31, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.55" lower_limit="34.861" upper_limit="112.233"/>
                    <measurement group_id="O2" value="143.08" lower_limit="79.875" upper_limit="256.286"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" lower_limit="4.825" upper_limit="8.344"/>
                    <measurement group_id="O2" value="15.26" lower_limit="9.688" upper_limit="24.026"/>
                    <measurement group_id="O3" value="19.38" lower_limit="12.917" upper_limit="29.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 2 (n=31, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" lower_limit="4.819" upper_limit="8.483"/>
                    <measurement group_id="O2" value="17.49" lower_limit="10.923" upper_limit="28.003"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection in SRH Antibody Titer (Vero Antigen) of &gt;= 25 mm^2</title>
        <description>Seroprotection rate was measured by SRH antibody titer (Vero Antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroprotection rate was defined as the percentage of participants with SRH antibody titer of &gt;=25 mm^2. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection in SRH Antibody Titer (Vero Antigen) of &gt;= 25 mm^2</title>
          <description>Seroprotection rate was measured by SRH antibody titer (Vero Antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroprotection rate was defined as the percentage of participants with SRH antibody titer of &gt;=25 mm^2. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.000" upper_limit="10.888"/>
                    <measurement group_id="O2" value="75.0" lower_limit="56.595" upper_limit="88.538"/>
                    <measurement group_id="O3" value="81.8" lower_limit="64.540" upper_limit="93.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="2.186" upper_limit="27.352"/>
                    <measurement group_id="O2" value="87.1" lower_limit="70.166" upper_limit="96.370"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" lower_limit="18.572" upper_limit="53.193"/>
                    <measurement group_id="O2" value="90.6" lower_limit="74.977" upper_limit="98.023"/>
                    <measurement group_id="O3" value="97.0" lower_limit="84.241" upper_limit="99.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="68.336" upper_limit="96.111"/>
                    <measurement group_id="O2" value="96.8" lower_limit="83.298" upper_limit="99.918"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="5.275" upper_limit="32.788"/>
                    <measurement group_id="O2" value="71.9" lower_limit="53.253" upper_limit="86.254"/>
                    <measurement group_id="O3" value="81.8" lower_limit="64.540" upper_limit="93.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" lower_limit="12.734" upper_limit="47.238"/>
                    <measurement group_id="O2" value="83.9" lower_limit="66.273" upper_limit="94.548"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion in SRH Antibody Titer (Vero Antigen)</title>
        <description>Seroconversion rate was measured by SRH antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroconversion rate was defined as the percentage of participants achieving a minimal 50% increase from baseline (with a baseline SRH antibody titer of &gt;4 mm^2), or achieving a SRH antibody titer of &gt;=25 mm^2 (with baseline SRH antibody titer of &lt;=4 mm^2) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain). Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion in SRH Antibody Titer (Vero Antigen)</title>
          <description>Seroconversion rate was measured by SRH antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Seroconversion rate was defined as the percentage of participants achieving a minimal 50% increase from baseline (with a baseline SRH antibody titer of &gt;4 mm^2), or achieving a SRH antibody titer of &gt;=25 mm^2 (with baseline SRH antibody titer of &lt;=4 mm^2) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain). Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.000" upper_limit="10.888"/>
                    <measurement group_id="O2" value="75.0" lower_limit="56.595" upper_limit="88.538"/>
                    <measurement group_id="O3" value="54.5" lower_limit="36.351" upper_limit="71.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="2.186" upper_limit="27.352"/>
                    <measurement group_id="O2" value="87.1" lower_limit="70.166" upper_limit="96.370"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="7.208" upper_limit="36.439"/>
                    <measurement group_id="O2" value="40.6" lower_limit="23.698" upper_limit="59.355"/>
                    <measurement group_id="O3" value="51.5" lower_limit="33.544" upper_limit="69.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" lower_limit="52.762" upper_limit="87.266"/>
                    <measurement group_id="O2" value="58.1" lower_limit="39.076" upper_limit="75.452"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="3.513" upper_limit="28.995"/>
                    <measurement group_id="O2" value="56.3" lower_limit="37.663" upper_limit="73.636"/>
                    <measurement group_id="O3" value="57.6" lower_limit="39.215" upper_limit="74.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="10.298" upper_limit="43.540"/>
                    <measurement group_id="O2" value="64.5" lower_limit="45.370" upper_limit="80.773"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFI in SRH Antibody Titer (Vero Antigen) From Baseline to 21 Days After Each Vaccination</title>
        <description>GMFI from baseline in SRH antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in SRH Antibody Titer (Vero Antigen) From Baseline to 21 Days After Each Vaccination</title>
          <description>GMFI from baseline in SRH antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination for all groups. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0000">95% confidence interval was not calculable because SRH antibody titers of Pre-vaccination and Post-vaccinations in all participants were same.</measurement>
                    <measurement group_id="O2" value="3.8815" lower_limit="2.91105" upper_limit="5.17543"/>
                    <measurement group_id="O3" value="3.0063" lower_limit="2.06690" upper_limit="4.37270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2706" lower_limit="0.99257" upper_limit="1.62639"/>
                    <measurement group_id="O2" value="4.1427" lower_limit="3.11949" upper_limit="5.50159"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4480" lower_limit="1.18483" upper_limit="1.76972"/>
                    <measurement group_id="O2" value="1.7522" lower_limit="1.41051" upper_limit="2.17678"/>
                    <measurement group_id="O3" value="2.0947" lower_limit="1.57731" upper_limit="2.78168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9597" lower_limit="3.52649" upper_limit="6.97548"/>
                    <measurement group_id="O2" value="2.2506" lower_limit="1.67926" upper_limit="3.01629"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n= 32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2209" lower_limit="0.97777" upper_limit="1.52445"/>
                    <measurement group_id="O2" value="3.6157" lower_limit="2.38627" upper_limit="5.47866"/>
                    <measurement group_id="O3" value="2.6846" lower_limit="1.92487" upper_limit="3.74409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B:21 days after Vaccination 2 (n= 29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2979" lower_limit="1.59954" upper_limit="3.30117"/>
                    <measurement group_id="O2" value="4.4759" lower_limit="3.05031" upper_limit="6.56777"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT of SRH Antibody Titer (Vero Antigen)</title>
        <description>GMT of SRH antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
        <time_frame>Day 22 (21 days after Vaccination 1 for all groups), Day 43 (21 days after Vaccination 2 for 6-35 months old group and 3-12 years old group)</time_frame>
        <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-850 0.25 mL: 6-35 Months</title>
            <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O2">
            <title>TAK-850 0.5 mL: 3-12 Years</title>
            <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
          </group>
          <group group_id="O3">
            <title>TAK-850 0.5 mL: 13-19 Years</title>
            <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT of SRH Antibody Titer (Vero Antigen)</title>
          <description>GMT of SRH antibody titer (Vero antigen) for each of the three strains (A/H1N1 strain, A/H3N2 strain, B strain), 21 days after each vaccination. Analysis after Vaccination 2 is only applicable for 6-35 months old group and 3-12 years old group.</description>
          <population>All participants included in the FAS (all participants who received at least 1 dose of study vaccination) who had data available for specified strain at specified post-baseline time points.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0000">95% confidence interval was not calculable because SRH antibody titers of Pre-vaccination and Post-vaccinations in all participants were same.</measurement>
                    <measurement group_id="O2" value="26.8737" lower_limit="20.52041" upper_limit="35.19414"/>
                    <measurement group_id="O3" value="32.3664" lower_limit="25.74333" upper_limit="40.69349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0822" lower_limit="3.97027" upper_limit="6.50558"/>
                    <measurement group_id="O2" value="30.9216" lower_limit="24.14566" upper_limit="39.59911"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2879" lower_limit="8.09586" upper_limit="18.65065"/>
                    <measurement group_id="O2" value="40.3869" lower_limit="31.13697" upper_limit="52.38484"/>
                    <measurement group_id="O3" value="61.7091" lower_limit="53.35048" upper_limit="71.37721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4564" lower_limit="32.19850" upper_limit="50.83224"/>
                    <measurement group_id="O2" value="55.3238" lower_limit="48.82904" upper_limit="62.68238"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 1 (n=32, 32, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5038" lower_limit="4.44742" upper_limit="9.51111"/>
                    <measurement group_id="O2" value="35.8443" lower_limit="25.16079" upper_limit="51.06422"/>
                    <measurement group_id="O3" value="38.2075" lower_limit="29.71344" upper_limit="49.12974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B: 21 days after Vaccination 2 (n=29, 31, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8420" lower_limit="7.20922" upper_limit="16.30540"/>
                    <measurement group_id="O2" value="44.8583" lower_limit="36.23158" upper_limit="55.53899"/>
                    <measurement group_id="O3" value="NA">Data is not required for this age group because Vaccination 2 is not planned for 13-19 years old group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TAEs are AEs, regardless of relationship to drug, that occur or worsen after first dose of study vaccine and no more than 21 days after the last dose (up to Day 43 for 6-35 months old group and 3-12 years old group, up to Day 22 for 13-19 years old group)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAK-850 0.25 mL: 6-35 Months</title>
          <description>Participants aged 6 to 35 months received TAK-850 0.25 mL (15 microgram [mcg]/0.5 mL of hemagglutinin [HA] antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
        </group>
        <group group_id="E2">
          <title>TAK-850 0.5 mL: 3-12 Years</title>
          <description>Participants aged 3 to 12 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 and 22 in a treatment period of 43 days.</description>
        </group>
        <group group_id="E3">
          <title>TAK-850 0.5 mL: 13-19 Years</title>
          <description>Participants aged 13 to 19 years received TAK-850 0.5 mL (15 mcg/0.5 mL of HA antigen per strain), injection, intramuscularly on Day 1 in a treatment period of 22 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Irritability postvaccinal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

